PharmTech Weekly Roundup – Week of September 8, 2025

In this new PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage.

Collectively, the week’s coverage discusses critical trends and advancements in the pharmaceutical industry, primarily focusing on insights from the PDA Regulatory Conference 2025, held September 8-10 in Washington, DC. A significant theme across our conference coverage is the increasing integration of artificial intelligence (AI) into various aspects of pharmaceutical operations, including supply chain management, quality control, and manufacturing, emphasizing the need for robust data governance, human oversight, and regulatory compliance.

We also address the importance of quality assurance and adherence to FDA regulations, detailing strategies for effective remediation, strengthening responses to inspection findings, and fostering a strong quality culture from leadership down. Additionally, there are discussions on digital transformation in workforce training, highlighting how modern learning management systems, virtual reality, and AI can enhance practical skills and continuous learning within the industry. Check out our interview with key PDA experts who provide key highlights from the conference.

Outside of our PDA Regulatory Conference coverage, we present real-world data on a new epinephrine nasal spray, showcasing its comparable effectiveness to traditional injections and its approval as a non-injection alternative for anaphylaxis; the European Commission's decision to continue allowing titanium dioxide in medicines, despite its ban in food; and findings from a Capgemini Research Institute survey of 1000 senior executives across various sectors, identifying key priorities and challenges for supply chain resilience.